Core Insights - Coty Inc. is under investigation for potential violations of federal securities laws, as announced by Bleichmar Fonti & Auld LLP [1][2] - The investigation arises amid concerns over Coty's reported demand for Prestige fragrances, which constitute 60% of its revenues, while actual retailer inventory levels suggest overstocking due to declining demand [2] Financial Performance - Coty reported disappointing financial results for Q4 and FY 2025, citing issues such as delays in identifying weaknesses in U.S. execution, retailer inventory buildup, and headwinds from previous fiscal year innovations [3] - The company's stock price fell by $1.05, a decline of over 21%, from $4.86 on August 20, 2025, to $3.81 on August 21, 2025, following the release of these results [3]

Core Viewpoint - A class action lawsuit has been filed against Baxter International Inc. and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Northern District of Illinois, captioned Electrical Workers Pension Fund, Local 103, I.B.E.W. v. Baxter International Inc., et al., No. 1:25-cv-12672 [3]. - Investors have until December 15, 2025, to request to be appointed to lead the case [3]. Group 2: Product Issues - Baxter's Novum IQ Large Volume pump, a key growth driver, has faced serious malfunctions, including under- and over-medication of patients, since its launch in Canada in 2020 [4][5]. - The company previously claimed that the Novum LVP had "the most advanced safety features" and would provide "a safer delivery of medication," which is now alleged to be misleading [5]. Group 3: Stock Impact - Following the announcement on July 31, 2025, that Baxter would "voluntarily and temporarily pause shipments and planned installations" of the Novum LVP, the stock price fell by $6.29, or over 22%, from $28.05 to $21.76 per share [6].

Core Viewpoint - The Dow class action lawsuit alleges that Dow Inc. and its executives made misleading statements regarding the company's financial health and ability to manage macroeconomic challenges, leading to significant investor losses during the specified class period [3][4][5]. Summary by Sections Class Action Details - The class action lawsuit, titled Sarti v. Dow Inc., is open for investors who purchased Dow securities between January 30, 2025, and July 23, 2025, to seek appointment as lead plaintiff by October 28, 2025 [1][6]. Allegations Against Dow - The lawsuit claims that Dow overstated its ability to handle macroeconomic and tariff-related challenges, and understated the negative impacts of competitive pressures, softening global sales, and product oversupply on its business [3][4]. - On June 23, 2025, BMO Capital downgraded Dow's stock from "Market Perform" to "Underperform," reducing the price target from $29.00 to $22.00, which was followed by a stock price drop of over 3% [4]. - Dow reported a non-GAAP loss per share of $0.42 for Q2 2025, significantly worse than the expected loss of approximately $0.17 to $0.18, with net sales of $10.1 billion reflecting a 7.3% year-over-year decline [5]. Financial Impact - Following the disappointing Q2 results, Dow announced a dividend cut from $0.70 to $0.35 per share, citing the need for financial flexibility in a challenging macroeconomic environment, which led to a stock price decline of over 17% [5]. Legal Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Dow securities during the class period to seek lead plaintiff status, which enables them to act on behalf of all class members [6]. About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [7][8].

Core Viewpoint - Halper Sadeh LLC is investigating the fairness of the merger between Nicolet Bankshares, Inc. and MidWestOne Financial Group, Inc. for Nicolet shareholders [1][3]. Group 1: Investigation Details - The investigation focuses on whether Nicolet and its board violated federal securities laws and breached fiduciary duties by not obtaining the best possible consideration for shareholders and failing to disclose all material information necessary for assessing the merger [3]. - Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures, and other relief related to the proposed transaction [3]. Group 2: Legal Rights and Contact Information - Nicolet shareholders are encouraged to contact Halper Sadeh LLC to learn more about their legal rights and options regarding the merger [2]. - The firm operates on a contingent fee basis, meaning shareholders would not be responsible for out-of-pocket legal fees or expenses [3].

Core Viewpoint - The MoonLake class action lawsuit alleges that MoonLake Immunotherapeutics and its executives violated the Securities Exchange Act of 1934, with claims centered around misleading statements regarding the efficacy of their drug candidate sonelokimab (SLK) compared to a competitor's product [1][3][4]. Group 1: Lawsuit Details - The lawsuit is titled Peters v. MoonLake Immunotherapeutics and is filed in the Southern District of New York [1]. - The class action seeks to represent purchasers or acquirers of MoonLake common stock during the class period [1][2]. - The lead plaintiff motions must be filed by December 15, 2025 [2]. Group 2: Company and Product Information - MoonLake is a clinical stage biotechnology company focused on therapies for inflammatory skin and joint diseases [3]. - SLK is the company's sole drug candidate, primarily developed for treating hidradenitis suppurativa (HS) [3]. Group 3: Allegations Against MoonLake - The lawsuit claims that MoonLake made false statements regarding SLK's clinical benefits, asserting that SLK and BIMZELX share the same molecular targets and that SLK's unique structure would not provide superior efficacy [4]. - On September 28, 2025, MoonLake announced Phase 3 VELA program results indicating SLK did not demonstrate competitive efficacy against BIMZELX, leading to a nearly 90% drop in stock price [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of MoonLake Immunotherapeutics during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1][3]. Group 1: Class Action Details - Investors who bought MoonLake common stock between March 10, 2024, and September 29, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the court to serve as lead plaintiff by December 15, 2025 [3][5]. - The lawsuit claims that defendants made false or misleading statements regarding the efficacy of their product SLK compared to traditional monoclonal antibodies, leading to investor damages when the truth was revealed [5]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in recovering significant amounts for investors [4]. - The firm has been recognized for its achievements in securities class action settlements, including a notable settlement against a Chinese company and ranking highly in the number of settlements achieved [4].

Core Viewpoint - A class action securities lawsuit has been filed against Fluor Corporation, alleging securities fraud that negatively impacted investors between February 18, 2025, and July 31, 2025 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that Fluor Corporation made false statements regarding the costs associated with its infrastructure projects, which were increasing due to subcontractor design errors, price hikes, and scheduling delays [2]. - It is alleged that these issues, along with reduced capital spending from customers and economic uncertainty, were likely to have a significant negative impact on the Company's business and financial results [2]. - The financial guidance provided by Fluor for FY 2025 is claimed to be unreliable and overstated regarding the effectiveness of its risk mitigation strategies and the impact of economic uncertainty [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until November 14, 2025, to request to be appointed as lead plaintiff in the lawsuit [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, and participation does not require serving as a lead plaintiff [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Core Viewpoint - A class action securities lawsuit has been filed against KBR, Inc. alleging securities fraud that affected investors between May 6, 2025, and June 19, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that KBR, Inc. made false statements regarding its partnership with HomeSafe, despite knowing that the U.S. Department of Defense had concerns about HomeSafe's ability to fulfill a global household goods contract [2]. - It is alleged that the defendants' statements about KBR's business operations and prospects were materially false and misleading, lacking a reasonable basis during the relevant time [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until November 18, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Group 1 - Halper Sadeh LLC is investigating Heidrick & Struggles International, Inc. for potential violations related to its sale to a consortium led by Advent International and Corvex Private Equity for $59.00 per share in cash [1] - Vimeo, Inc. is also under investigation for its sale to Bending Spoons for $7.85 per share in cash [2] - The firm may seek increased consideration for shareholders and additional disclosures regarding the proposed transactions [3] Group 2 - Shareholder involvement is emphasized as a means to improve company policies and enhance shareholder value [4] - Halper Sadeh LLC represents investors globally who have experienced securities fraud and corporate misconduct, recovering millions for defrauded investors [5]

Core Viewpoint - A class action securities lawsuit has been filed against Cytokinetics, alleging securities fraud related to misleading statements about the New Drug Application (NDA) for aficamten, which may have led to significant investor losses [1][2]. Case Details - The lawsuit claims that Cytokinetics made materially false and misleading statements regarding the expected timeline for FDA approval of aficamten, specifically indicating approval in the second half of 2025 based on a September 26, 2025 PDUFA date [2]. - It is alleged that the company failed to disclose critical risks associated with not submitting a Risk Evaluation and Mitigation Strategy (REMS), which could delay the regulatory process [2]. - During an earnings call on May 6, 2025, it was revealed that the company had discussions with the FDA about safety monitoring and risk mitigation but chose to submit the NDA without a REMS, misleading investors about the regulatory timeline [2]. Next Steps - Investors who suffered losses in Cytokinetics during the specified period have until November 17, 2025, to request appointment as lead plaintiff, although participation does not require serving in this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Why Levi & Korsinsky - Levi & Korsinsky has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the U.S. [4].